MARKET

ZTS

ZTS

Zoetis
NYSE

Real-time Quotes | Nasdaq Last Sale

202.86
+2.32
+1.16%
Opening 12:30 07/23 EDT
OPEN
201.73
PREV CLOSE
200.54
HIGH
203.14
LOW
200.65
VOLUME
307.38K
TURNOVER
--
52 WEEK HIGH
203.14
52 WEEK LOW
141.41
MARKET CAP
96.31B
P/E (TTM)
54.69
1D
5D
1M
3M
1Y
5Y
The ProShares Pet Care ETF — Invest in Every Stage of Pet Care
Investor Place · 5h ago
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
Zacks.com · 1d ago
Zoetis vs. Chewy: Which Pet Stock is a Better Buy?
StockNews.com · 1d ago
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
Zacks.com · 1d ago
CHICAGO TRUST Co NA Buys Abbott Laboratories, Microsoft Corp, Danaher Corp, Sells Apple Inc, ...
GuruFocus News · 1d ago
Zoetis Stock Is Estimated To Be Significantly Overvalued
GuruFocus News · 6d ago
Zoetis Stock Soared During the Pandemic. This Analyst Says the Run Is Over.
marketwatch.com · 6d ago
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study
Zacks.com · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZTS. Analyze the recent business situations of Zoetis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZTS stock price target is 204.50 with a high estimate of 238.00 and a low estimate of 170.00.
EPS
Institutional Holdings
Institutions: 1.73K
Institutional Holdings: 463.47M
% Owned: 97.62%
Shares Outstanding: 474.77M
TypeInstitutionsShares
Increased
594
21.77M
New
111
2.57M
Decreased
458
21.78M
Sold Out
105
1.14M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.75%
Pharmaceuticals & Medical Research
+0.66%
Key Executives
Non-Executive Chairman/Independent Director
Michael Mccallister
Chief Executive Officer/Director
Kristin Peck
Chief Financial Officer/Executive Vice President
Wetteny Joseph
Chief Human Resource Officer/Executive Vice President
Roxanne Lagano
Executive Vice President/Chief Information Officer
Wafaa Mamilli
Executive Vice President/General Counsel/Secretary
Heidi Chen
Executive Vice President
Timothy Bettington
Executive Vice President
Robert Kelly
Executive Vice President
Catherine Knupp
Executive Vice President
J. Michael McFarland
Executive Vice President
Abhay Nayak
Executive Vice President
Sherry Pudloski
Executive Vice President
Roman Trawicki
Independent Director
Paul Bisaro
Independent Director
Frank D'amelio
Independent Director
Sanjay Khosla
Independent Director
Antoinette Leatherberry
Independent Director
Gregory Norden
Independent Director
Louise Parent
Independent Director
Willie Reed
Independent Director
Linda Rhodes
Independent Director
Robert Scully
Declaration Date
Dividend Per Share
Ex-Div Date
05/20/2021
Dividend USD 0.25
07/20/2021
02/10/2021
Dividend USD 0.25
04/20/2021
12/09/2020
Dividend USD 0.25
01/19/2021
10/07/2020
Dividend USD 0.2
10/20/2020
05/20/2020
Dividend USD 0.2
07/16/2020
02/11/2020
Dividend USD 0.2
04/16/2020
12/11/2019
Dividend USD 0.2
01/16/2020
10/03/2019
Dividend USD 0.164
10/21/2019
05/15/2019
Dividend USD 0.164
07/18/2019
02/12/2019
Dividend USD 0.164
04/17/2019
12/12/2018
Dividend USD 0.164
01/17/2019
10/10/2018
Dividend USD 0.126
11/19/2018
05/15/2018
Dividend USD 0.126
07/19/2018
02/13/2018
Dividend USD 0.126
04/19/2018
12/11/2017
Dividend USD 0.126
01/18/2018
10/05/2017
Dividend USD 0.105
11/08/2017
05/22/2017
Dividend USD 0.105
06/13/2017
02/15/2017
Dividend USD 0.105
04/04/2017
12/07/2016
Dividend USD 0.105
01/18/2017
10/06/2016
Dividend USD 0.095
11/01/2016
  • All
  • Financials
  • Insiders
More
About ZTS
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Webull offers kinds of Zoetis Inc stock information, including NYSE:ZTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZTS stock methods without spending real money on the virtual paper trading platform.